Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Opya

Explore full profile

In-home early intervention autism therapy for children

San Mateo, United StatesFounded 2015Biotech & Life Sciences
Valuation $50–100M Last recorded · 2021
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Opya and the history behind them.

About Opya

Opya specializes in early intervention autism therapy for children from 18 months to 6 years old. The company was founded in 2015 by Jonathan Wright, who was inspired by his mother's career as an adolescent psychiatrist. His background of over 20 years in healthcare and technology led him to establish Opya to provide a better therapy option for young children with autism.

The company provides comprehensive, in-home Applied Behavior Analysis (ABA) therapy, which is complemented by telehealth services for speech, occupational, and feeding therapies. This model focuses on providing care in the child's natural environment to promote meaningful learning. Opya also offers center-based care options and uses technology to facilitate communication between clinicians, families, and staff. Its business model relies on in-network contracts with both Medicaid and commercial payers in California, making its services accessible to a wide range of families. Opya serves families across Northern and Southern California.

A significant milestone for Opya is earning a 3-year Behavioral Health Center of Excellence (BHCOE) accreditation, highlighting its commitment to clinical quality. The company has also expanded its services through acquisitions, such as the purchase of the Center for Autism Spectrum Therapy. In 2021, Opya raised $15.4 million in a Series A funding round to scale its clinical care and accelerate product innovation. Investors include Panoramic Ventures, the SB Opportunity Fund, and the Disability Opportunity Fund.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
San Mateo, United States
Employees
96
Open positions
None listed
Dealroom signal
63.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Investment activity
1 company, latest Mar 2016
Capital deployed
—
Preferred round
ACQUISITION

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2021 $15M $62M Altitude Ventures · Raven One Ventures · Panoramic Ventures · The Disability Opportunity Fund —
SEEDEquity / VC Oct 2017 $3.9M $16M SpringRock Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Opya website traffic

Latest recorded traffic for Opya is 4K monthly website visits, down 25.9% over the last three months. Opya's team declined 4% over the past year.

Latest monthly visits4K 3-month web change-25.9% 1-year team growth-4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Lyopor3D collagen scaffold for 3D cell culture, suitable for testing the behavior of a wide range of cells in their natural 3D environment Brno, Czechia Operational — $132K $528K
Evergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals Jersey City, United States Acquired
A.D.A.M.A.D.A.M. is a biotech company that targets artificial bones and tissues market, using it proprietary 3D printing technology. A.D.A.M. focuses on 3D printing of different tissues (initially bones) made of patented organic materials, which can be scala Stamford, United States Operational
AC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients Ecublens, Switzerland Operational
Sapreme TechnologieDevelops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics Driebergen-Rijsenburg, Netherlands Operational
CerecinHealthcare company that develops a novel evidence-based therapeutics, and products that aim to help people Denver, United States Operational
Skyhawk TherapeuticsA drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression Waltham, United States Operational
Onkos SurgicalSurgical oncology company that develops implants and instruments for musculoskeletal tumor patients Parsippany-Troy Hills, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • SpringRock Ventures

Series A7 investors entered at this stage

  • Panoramic Ventures
  • Altitude Ventures
  • Raven One Ventures
  • The Disability Opportunity Fund
  • SB Opportunity Fund
  • Divergent Investments
  • BIP Ventures

Other known investors1 additional known investor

  • LearnStart
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States97.9%
🇫🇷 France2.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Opya on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Opya’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.